ArticleFrontiers in oncology2024

Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSCLC patient: a case report and literature review.

Xin Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.